Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Patterns of care and survival outcomes for laryngeal small cell cancer.

Lin AJ, Gabani P, Fischer-Valuck B, Rudra S, Gay H, Daly M, Oppelt P, Jackson R, Rich J, Paniello R, Zevallos J, Adkins D, Thorstad W.

Head Neck. 2019 Mar;41(3):722-729. doi: 10.1002/hed.25430. Epub 2018 Dec 10.

PMID:
30785231
2.

Outcomes of relapsed human papillomavirus-related oropharyngeal squamous cell carcinoma treated with curative intent.

Pipkorn P, Sinha P, Kallogjeri D, Adkins D, Thorstad WT, Rich JT, Jackson RS.

Head Neck. 2018 Dec 11. doi: 10.1002/hed.25557. [Epub ahead of print]

PMID:
30536710
3.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.

PMID:
30509740
4.

Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers.

Lin AJ, Rao YJ, Chin RI, Campian J, Mullen D, Thotala D, Daly M, Gay H, Oppelt P, Hallahan D, Adkins D, Thorstad W.

Oral Oncol. 2018 Nov;86:1-7. doi: 10.1016/j.oraloncology.2018.08.008. Epub 2018 Sep 7.

PMID:
30409288
5.

Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer.

Gay HA, Oh JH, Apte AP, Daly MD, Adkins DR, Rich J, Oppelt PJ, Dyk PT, Mullen DF, Eschen L, Chin RI, Nussenbaum B, Haughey BH, Thorstad WL, Deasy JO.

Clin Transl Radiat Oncol. 2018 Sep 4;13:1-6. doi: 10.1016/j.ctro.2018.08.004. eCollection 2018 Nov.

6.

Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity.

Campbell KM, Lin T, Zolkind P, Barnell EK, Skidmore ZL, Winkler AE, Law JH, Mardis ER, Wartman LD, Adkins DR, Chernock RD, Griffith M, Uppaluri R, Griffith OL.

Cell Rep. 2018 Aug 21;24(8):2167-2178. doi: 10.1016/j.celrep.2018.07.058.

7.

Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging.

Floberg JM, DeWees TA, Chin RI, Garsa AA, Dehdashti F, Nussenbaum B, Oppelt PJ, Adkins DR, Gay HA, Thorstad WL.

Head Neck. 2018 Oct;40(10):2280-2287. doi: 10.1002/hed.25337. Epub 2018 Jul 26.

PMID:
30051553
8.

Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care.

Gabani P, Barnes J, Lin AJ, Rudra S, Oppelt P, Adkins D, Rich JT, Zevallos JP, Daly MD, Gay HA, Thorstad WL.

Cancer Med. 2018 Aug;7(8):3592-3603. doi: 10.1002/cam4.1626. Epub 2018 Jul 14.

9.

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.

Adkins D, Mehan P, Ley J, Siegel MJ, Siegel BA, Dehdashti F, Jiang X, Salama NN, Trinkaus K, Oppelt P.

Lancet Oncol. 2018 Aug;19(8):1082-1093. doi: 10.1016/S1470-2045(18)30350-4. Epub 2018 Jul 11.

PMID:
30001987
10.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

PMID:
29931076
11.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
12.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
13.

Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.

Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS.

Cell Death Dis. 2018 Jan 5;9(1):5. doi: 10.1038/s41419-017-0029-0.

14.

Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.

Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, Agarwala SS, Venigalla ML, Chen Y, Zhen W, Mould DR, Holmlund JT, Brill JM, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):427-435. doi: 10.1016/j.ijrobp.2017.10.019. Epub 2017 Oct 16.

15.

Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.

Hanna GJ, Adkins DR, Zolkind P, Uppaluri R.

Oral Oncol. 2017 Oct;73:65-69. doi: 10.1016/j.oraloncology.2017.08.008. Epub 2017 Aug 17. Review.

PMID:
28939078
16.

Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil.

Chin RI, Rao YJ, Hwang MY, Spencer CR, Pierro M, DeWees T, Patel P, Sinha P, Gay HA, Daly M, Haughey BH, Nussenbaum B, Adkins DR, Lewis JS Jr, Thorstad WL.

Cancer. 2017 Dec 1;123(23):4594-4607. doi: 10.1002/cncr.30931. Epub 2017 Sep 7.

17.

Trials in head and neck oncology: Evolution of perioperative adjuvant therapy.

Zenga J, Pipkorn P, Adkins DR, Thorstad WL, Nussenbaum B.

Oral Oncol. 2017 Sep;72:80-89. doi: 10.1016/j.oraloncology.2017.07.012. Epub 2017 Jul 15. Review. No abstract available.

PMID:
28797466
18.

nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.

Adkins D, Ley J, Oppelt P, Wildes TM, Gay HA, Daly M, Rich J, Paniello RC, Jackson R, Pipkorn P, Nussenbaum B, Trinkaus K, Thorstad W.

Oral Oncol. 2017 Sep;72:26-31. doi: 10.1016/j.oraloncology.2017.07.001. Epub 2017 Jul 8.

PMID:
28797458
19.

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O.

Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep.

20.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
21.

NCCN Guidelines Insights: Bone Cancer, Version 2.2017.

Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2017 Feb;15(2):155-167.

PMID:
28188186
22.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.

Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.

23.

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.

Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS Jr, Adkins DR.

Clin Cancer Res. 2017 May 1;23(9):2186-2194. doi: 10.1158/1078-0432.CCR-16-1469. Epub 2016 Nov 9.

24.

Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.

Ley J, Wildes TM, Daly K, Oppelt P, Adkins D.

Med Oncol. 2017 Feb;34(2):28. doi: 10.1007/s12032-017-0884-7. Epub 2017 Jan 11.

PMID:
28078561
25.

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma.

Chatzkel J, Lewis JS Jr, Ley JC, Wildes TM, Thorstad W, Gay H, Daly M, Jackson R, Rich J, Paniello R, Nussenbaum B, Liu J, Siegel BA, Dehdashti F, Adkins D.

Head Neck Pathol. 2017 Sep;11(3):338-345. doi: 10.1007/s12105-016-0775-9. Epub 2016 Dec 26.

26.

Outcomes of surgically treated human papillomavirus-related oropharyngeal squamous cell carcinoma with N3 disease.

Zenga J, Haughey BH, Jackson RS, Adkins DR, Aranake-Chrisinger J, Bhatt N, Gay HA, Kallogjeri D, Martin EJ, Moore EJ, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B.

Laryngoscope. 2017 Sep;127(9):2033-2037. doi: 10.1002/lary.26455. Epub 2016 Dec 23.

PMID:
28008626
27.

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study.

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O.

J Biotechnol. 2016 Dec 10;239:115-125. doi: 10.1016/j.jbiotec.2016.10.010. Epub 2016 Oct 13.

28.

Reevaluation of postoperative radiation dose in the management of human papillomavirus-positive oropharyngeal cancer.

Chin RI, Spencer CR, DeWees T, Hwang MY, Patel P, Sinha P, Gay HA, Haughey BH, Nussenbaum B, Adkins DR, Lewis JS Jr, Thorstad WL.

Head Neck. 2016 Nov;38(11):1643-1649. doi: 10.1002/hed.24486. Epub 2016 May 6.

PMID:
27152851
29.

A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.

Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA.

Cell Death Dis. 2016 Oct 13;7(10):e2406. doi: 10.1038/cddis.2016.232.

30.

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S.

Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20.

PMID:
27688102
31.

nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.

Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Gay HA, Daly M, Rich J, Paniello R, Uppaluri R, Jackson R, Trinkaus K, Nussenbaum B.

Oral Oncol. 2016 Oct;61:1-7. doi: 10.1016/j.oraloncology.2016.07.015. Epub 2016 Jul 29.

32.

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Michel L, Ley J, Wildes TM, Schaffer A, Robinson A, Chun SE, Lee W, Lewis J Jr, Trinkaus K, Adkins D.

Oral Oncol. 2016 Jul;58:41-8. doi: 10.1016/j.oraloncology.2016.05.011. Epub 2016 May 28.

33.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK.

Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464.

34.

High E6 Gene Expression Predicts for Distant Metastasis and Poor Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma.

Khwaja SS, Baker C, Haynes W, Spencer CR, Gay H, Thorstad W, Adkins DR, Nussenbaum B, Chernock RD, Lewis JS Jr, Wang X.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1132-41. doi: 10.1016/j.ijrobp.2016.03.001. Epub 2016 Mar 10.

PMID:
27209503
35.

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.

Soulières D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D.

BMC Cancer. 2016 Jan 14;16:19. doi: 10.1186/s12885-016-2064-0.

36.

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Rischin D, Spigel DR, Adkins D, Wein R, Arnold S, Singhal N, Lee O, Murugappan S.

Head Neck. 2016 Apr;38 Suppl 1:E1756-61. doi: 10.1002/hed.24311. Epub 2015 Dec 17.

PMID:
26681429
37.

Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.

Zenga J, Wilson M, Adkins DR, Gay HA, Haughey BH, Kallogjeri D, Michel LS, Paniello RC, Rich JT, Thorstad WL, Nussenbaum B.

JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1118-27. doi: 10.1001/jamaoto.2015.0764.

PMID:
25902372
38.

RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?

Adkins D, Ley J, Wildes TM, Michel L.

J Clin Oncol. 2015 Apr 1;33(10):1223-4. doi: 10.1200/JCO.2014.59.6908. Epub 2015 Feb 23. No abstract available.

PMID:
25713440
39.

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK.

Cancer Chemother Pharmacol. 2015 Mar;75(3):629-38. doi: 10.1007/s00280-015-2689-8. Epub 2015 Feb 12.

40.

Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.

Schell A, Ley J, Wu N, Trinkaus K, Wildes TM, Michel L, Thorstad W, Gay H, Lewis J, Rich J, Diaz J, Paniello RC, Nussenbaum B, Adkins DR.

Cancer Med. 2015 Apr;4(4):481-9. doi: 10.1002/cam4.382. Epub 2015 Jan 26.

41.

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, Bowles DW, Spira A, Levy B, Seetharamu N, Hausman D, Walker L, Rudin CM, Shirai K.

Oral Oncol. 2015 Apr;51(4):383-8. doi: 10.1016/j.oraloncology.2014.12.013. Epub 2015 Jan 13.

42.

Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients.

Verma V, Liu J, Eschen L, Danieley J, Spencer C, Lewis JS Jr, Diaz J, Piccirillo JF, Adkins DR, Nussenbaum B, Thorstad WL, Gay HA.

Radiat Oncol. 2015 Jan 9;10:8. doi: 10.1186/s13014-014-0314-3.

43.

Looking beyond the CRT paradigm: why induction chemotherapy is worthy of pursuit.

Adkins D, Ley J, Michel L, Wildes TM, Thorstad W, Rich J, Nussenbaum B.

Oral Oncol. 2015 Feb;51(2):103-4. doi: 10.1016/j.oraloncology.2014.11.018. Epub 2014 Dec 11. No abstract available.

PMID:
25497105
44.

Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma.

Ley J, Wildes T, El-Mofty S, Adkins D.

Ecancermedicalscience. 2014 Nov 13;8:480. doi: 10.3332/ecancer.2014.480. eCollection 2014.

45.

Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'.

Adkins D, Ley J.

Oral Oncol. 2014 Dec;50(12):e72. doi: 10.1016/j.oraloncology.2014.09.008. Epub 2014 Oct 2. No abstract available.

PMID:
25282254
46.

Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.

Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS.

Oncotarget. 2014 Oct 15;5(19):9281-94.

47.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN.

J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi: 10.1200/JCO.2013.54.3660. Epub 2014 Sep 2.

48.

Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.

Spencer CR, Gay HA, Haughey BH, Nussenbaum B, Adkins DR, Wildes TM, DeWees TA, Lewis JS Jr, Thorstad WL.

Cancer. 2014 Dec 15;120(24):3994-4002. doi: 10.1002/cncr.28938. Epub 2014 Aug 20.

49.

A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.

Adkins D, Ley J, Dehdashti F, Siegel MJ, Wildes TM, Michel L, Trinkaus K, Siegel BA.

Cancer Med. 2014 Dec;3(6):1493-501. doi: 10.1002/cam4.294. Epub 2014 Aug 1.

50.

Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.

Touma W, Koro SS, Ley J, Wildes TM, Michel L, Tao Y, Adkins D.

Oral Oncol. 2014 Sep;50(9):895-900. doi: 10.1016/j.oraloncology.2014.06.017. Epub 2014 Jul 15.

Supplemental Content

Loading ...
Support Center